Bispecific designs patent application
09 August 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces that it has submitted a patent
application in respect of the Company’s bispecific designs for antigen
display.
The Company uses antigens to generate and screen for specific antibodies
during the Antibody Discovery process. Fusion’s new designs for antigens
consist of two parts; the antigen part and a “reporter” part, referred
to as a “bispecific”. The Company believes that the use of a reporter
part, which can be any number of useful tags for various antibody
screening assays, will increase the success rate in identifying highly
potent antibodies from Fusion’s range of Antibody Discovery
technologies.
Simon Douglas, Chairman of Fusion, commented: “Our dedicated team of scientists continues to work on next generation antibody discovery, and we see significant opportunities in this field. We look forward to contributing to the growing body of research concerning the scope of antibody production and design, while also growing our patent portfolio."
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Simon Douglas, Chairman James Fair, Chief Financial Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve/Vivek Bhardwaj (Corporate
Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast-based Collaborative Research Organisation ("CRO")
company, listed on AIM, providing a range of antibody engineering
services for the development of antibodies for both therapeutic drug and
diagnostic applications.
Fusion provides a broad range of services in antibody generation,
development, characterisation, optimisation, and small-scale production.
These services include antigen expression, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRxTM platform and
cell line development, producing antibody generating stable cell lines
optimised for use downstream by the customer to produce material for
clinical trials. Since 2012, the Company has successfully sequenced and
expressed over 250 antibodies and successfully completed over 200
humanisation projects for its international customer base, which has
included eight of the top 10 global pharmaceutical companies by
revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge science.
In this work our world-class humanization and antibody optimization
platforms harness the power of natural somatic hypermutation (SHM) to
ensure the best molecule goes to the clinic. Fusion Antibodies' growth
strategy is based on enabling Pharma and Biotech companies get to the
clinic more effectively, using molecules with optimized therapeutic
profile and enhanced potential for successful development and approval
and, ultimately, on speeding up the drug discovery and development
process. Fusion's use of SHM to create a fully human antibody library to
capture the human antibody repertoire will address a continuing market
need in antibody discovery,
Fusion Antibodies' emphasis on antibody therapeutics is based on the size
and growth rate in the sector, with the market valued at $135.4 billion
in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%.
As of May 2021, there were 100 approved antibody therapies on the market
and more than 570 antibody therapies in clinical development.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
